This article explores the implications of the recently announced departure of FDA’s Office of Generic Drugs Director Gregory Geba, MD. Catalyst’s Nancy Bradish Myers offers insight on the future of the OGD, CDER Director Janet Woodcock’s plans to oversee the office as Acting Director during the search for a replacement and the ongoing Generic Drug User Fee Act commitments that the office must meet.

FDA Generics Director’s Departure Shows Why Chemistry Matters

The Pink Sheet

(subscription required)